1. ABOUT GARDP FOUNDATION
The Global Antibiotic Research & Development Partnership (GARDP Foundation) is a not-for-profit global health organization registered in Geneva, Switzerland. GARDP’s mission is to accelerate the development and access of treatments for drug-resistant bacterial infections. It does so by forging public-private partnerships all over the world to develop and expand access to treatments for serious bacterial infections and sepsis in adults, children and newborns, as well as sexually transmitted infections (STIs).
GARDP Foundation responds to the crisis in antimicrobial resistance. In 2015, the World Health Assembly, the decision-making body of the World Health Organization (WHO), adopted the Global Action Plan on Antimicrobial Resistance. The following year, to deliver on this plan, WHO and the Drugs for Neglected Diseases initiative created GARDP. In 2018, the GARDP Foundation was legally established as an independent entity.
Since then, GARDP Foundation has developed a portfolio of antibiotic treatments that targets WHO priority pathogens, priority diseases and key populations/regions that are especially affected by drug resistance. It is also pioneering new access initiatives with innovator, manufacturing and distribution partners.
As of 2024, the GARDP team consists of about 100 people who collectively share extensive cross-sector R&D and access experience. They work with the key public and private sector stakeholders and partners, such as the research and development community, donors, industry and implementing countries.
2. PROJECT BACKGROUND & PURPOSE OF THE RFP
Background to project
Brazil is one of the largest pharmaceutical markets in Latin America, with a dual healthcare system comprising a universal public system (Sistema Único de Saúde – SUS) and a substantial private sector. The public system covers the majority of the population through centralized and decentralized procurement mechanisms, while the private sector provides access through private hospitals, insurance schemes, and out-of-pocket expenditures. These two segments operate under different pricing, reimbursement, and access dynamics, which must be considered when assessing market potential and affordability.
Zoliflodacin is a first-in-class, single-dose oral antibiotic developed for the treatment of uncomplicated urogenital gonorrhoea caused by Neisseria gonorrhoeae, including strains resistant to currently available therapies. It belongs to a novel class of spiropyrimidinetriones and acts through inhibition of bacterial type II topoisomerases, offering a new mechanism of action and activity against multidrug-resistant strains, with no cross-resistance to existing antibiotics.
Gonorrhoea is a significant global public health concern, with a high and increasing burden and a well-documented capacity to develop resistance to multiple classes of antimicrobials, including last-line treatments. In this context, zoliflodacin addresses a critical unmet medical need and represents the first new antibiotic specifically developed for gonorrhoea in several decades. The product received marketing authorization from the United States Food and Drug Administration (FDA) in December 2025, based on evidence from a large Phase 3 clinical trial demonstrating non-inferiority to the current standard of care.
Zoliflodacin has been developed through a public–private partnership between the Global Antibiotic Research and Development Partnership (GARDP) and Innoviva Specialty Therapeutics, with a focus on enabling global access and supporting appropriate introduction strategies in low- and middle-income countries, including Brazil.
Given Brazil’s epidemiological context, the size and complexity of its healthcare system, and its potential role in regional access strategies, it is important to assess how zoliflodacin could be positioned across both public and private sectors. Differences in procurement mechanisms, reimbursement pathways, prescribing practices, and willingness to pay may influence uptake, volume projections, and financial sustainability. A structured analysis covering both segments is therefore required to inform pricing and access strategies and support planning for the introduction of zoliflodacin in Brazil.
Purpose of RFP
GARDP seeks to commission a consultancy to conduct a price sensitivity analysis and value assessment to develop a price-volume matrix for zoliflodacin across the public sector (SUS) and private sector in Brazil.
If you are interested to receive the complete documentation, please send an email to: RFP_Procurement@gardp.org.
Due/closing date: October 1st, 2026